Additionally, novel strategies aimed at enhancing gallbladder motility in insulin-resistant states provide another avenue for therapeutic intervention, collectively suggesting multiple pathways for developing more effective treatments for patients with concurrent MetS and GSD. The gene discussed is INS; the disease is metabolic syndrome.